Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been given an average rating of “Moderate Buy” by the five brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $7.40.

Several equities analysts recently issued reports on the stock. Stephens reiterated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th. StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Los Angeles Capital Management LLC bought a new position in Actinium Pharmaceuticals in the 3rd quarter worth $322,000. XTX Topco Ltd purchased a new stake in shares of Actinium Pharmaceuticals during the third quarter worth about $268,000. JPMorgan Chase & Co. raised its stake in Actinium Pharmaceuticals by 804.5% during the 4th quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock valued at $156,000 after purchasing an additional 110,141 shares during the period. Deutsche Bank AG lifted its holdings in Actinium Pharmaceuticals by 413.6% in the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock worth $155,000 after purchasing an additional 99,158 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Actinium Pharmaceuticals by 49.9% in the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares during the period. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Price Performance

Shares of NYSE:ATNM traded down $0.02 on Tuesday, hitting $1.11. The company’s stock had a trading volume of 54,284 shares, compared to its average volume of 179,769. Actinium Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $10.24. The company has a market capitalization of $34.47 million, a PE ratio of -0.79 and a beta of 0.10. The company has a 50-day simple moving average of $1.22 and a 200 day simple moving average of $1.49.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).